secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2026-06-03T13:02:51+00:00
Accession:  0001628280-26-040051
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Crescent Biopharma shareholders re-elect directors, ratify auditor, approve say-on-pay
--------------------------------------------------------------------------------

- Jonathan Violin, Ph.D. elected Class II director with 2,890,000 votes (all from preferred shares).
- Susan Moran, M.D., MSCE elected Class II director with 21,401,136 votes FOR; 136,056 WITHHELD.
- Ratification of PricewaterhouseCoopers as auditor approved with 21,049,101 FOR (1,452 against).
- Non-binding say-on-pay approved: 18,346,099 FOR; 300,217 AGAINST. Board set future vote every 1 year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000162828026040051/0001628280-26-040051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000162828026040051/cbio-20260602.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-040051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer